Journal
SEMINARS IN ARTHRITIS AND RHEUMATISM
Volume 51, Issue 1, Pages 43-48Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.semarthrit.2020.11.006
Keywords
Systemic lupus erythematosus; Biomarkers; Autoantibodies; Cytokines
Categories
Ask authors/readers for more resources
SLE is a complex autoimmune disease with challenges in early identification and timely treatment. Some patients may exhibit symptoms suggestive of iSLE, but not all progress to full SLE. Therefore, predictive biomarkers are needed to distinguish high-risk patients for early intervention.
Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease. A main challenge faced by clinicians is early identification of SLE, frequently resulting in diagnostic delay. Timely treatment, however, is important to limit disease progression, and prevent organ damage and mortality. Often, patients present with clinical symptoms and immunologic abnormalities suggestive of SLE, while not meeting classification criteria yet. This is referred to as incomplete SLE (iSLE). However, not all these patients will develop SLE. Therefore, there is need for predictive biomarkers that can distinguish patients at high risk of developing SLE, in order to allow early treatment. This article reviews the current literature on immunological changes in patients with stages preceding SLE, focusing on autoantibodies, type-I and -II interferons, and the complement system. We also provide an overview of possible predictive markers for progression to SLE that are applicable in daily clinical practice. (C) 2020 The Authors. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available